Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The prevalent KRAS exon 2 c.35 G>A mutation in metastatic colorectal cancer patients: A biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens?
Bruera G, Cannita K, Tessitore A, Russo A, Alesse E, Ficorella C, Ricevuto E. Bruera G, et al. Among authors: ricevuto e. Crit Rev Oncol Hematol. 2015 Mar;93(3):190-202. doi: 10.1016/j.critrevonc.2014.10.004. Epub 2014 Oct 16. Crit Rev Oncol Hematol. 2015. PMID: 25459669 Review.
"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study.
Bruera G, Santomaggio A, Cannita K, Baldi PL, Tudini M, De Galitiis F, Mancini M, Marchetti P, Antonucci A, Ficorella C, Ricevuto E. Bruera G, et al. Among authors: ricevuto e. BMC Cancer. 2010 Oct 19;10:567. doi: 10.1186/1471-2407-10-567. BMC Cancer. 2010. PMID: 20958992 Free PMC article. Clinical Trial.
Intensive chemotherapy of metastatic colorectal cancer: weighing between safety and clinical efficacy: Evaluation of Masi G, Loupakis F, Salvatore L, et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010;11:845-52.
Bruera G, Ricevuto E. Bruera G, et al. Among authors: ricevuto e. Expert Opin Biol Ther. 2011 Jun;11(6):821-4. doi: 10.1517/14712598.2011.582462. Expert Opin Biol Ther. 2011. PMID: 21545334 Clinical Trial.
Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab.
Bruera G, Cannita K, Giuliante F, Lanfiuti Baldi P, Vicentini R, Marchetti P, Nuzzo G, Antonucci A, Ficorella C, Ricevuto E. Bruera G, et al. Among authors: ricevuto e. Clin Colorectal Cancer. 2012 Jun;11(2):119-26. doi: 10.1016/j.clcc.2011.11.002. Epub 2011 Dec 27. Clin Colorectal Cancer. 2012. PMID: 22206922 Clinical Trial.
Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease.
Bruera G, Cannita K, Di Giacomo D, Lamy A, Troncone G, Dal Mas A, Coletti G, Frébourg T, Sabourin JC, Tosi M, Ficorella C, Ricevuto E. Bruera G, et al. Among authors: ricevuto e. BMC Med. 2012 Nov 8;10:135. doi: 10.1186/1741-7015-10-135. BMC Med. 2012. PMID: 23136868 Free PMC article.
139 results